MA45809A - Promédicaments de pth - Google Patents

Promédicaments de pth

Info

Publication number
MA45809A
MA45809A MA045809A MA45809A MA45809A MA 45809 A MA45809 A MA 45809A MA 045809 A MA045809 A MA 045809A MA 45809 A MA45809 A MA 45809A MA 45809 A MA45809 A MA 45809A
Authority
MA
Morocco
Prior art keywords
pth
medicines
pth prodrugs
pharmaceutical compositions
relates
Prior art date
Application number
MA045809A
Other languages
English (en)
Other versions
MA45809B1 (fr
Inventor
Felix Cleemann
Mathias Krusch
Guillaume Maitro
Kennett Sprogøe
Thomas Wegge
Joachim Zettler
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MA45809A publication Critical patent/MA45809A/fr
Publication of MA45809B1 publication Critical patent/MA45809B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La présente invention concerne des promédicaments à base de pth, des compositions pharmaceutiques comprenant de tels promédicaments à base de pth et leurs utilisations.
MA45809A 2016-03-01 2017-02-28 Promédicaments de pth MA45809B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16158048 2016-03-01
EP16179294 2016-07-13
EP16191484 2016-09-29
EP17155839 2017-02-13
PCT/EP2017/054550 WO2017148883A1 (fr) 2016-03-01 2017-02-28 Promédicaments de pth
EP17707559.5A EP3423103B1 (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Publications (2)

Publication Number Publication Date
MA45809A true MA45809A (fr) 2019-01-09
MA45809B1 MA45809B1 (fr) 2024-12-31

Family

ID=58185540

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045277A MA45277A (fr) 2016-03-01 2017-02-28 Promédicaments de pth
MA45809A MA45809B1 (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA045277A MA45277A (fr) 2016-03-01 2017-02-28 Promédicaments de pth

Country Status (30)

Country Link
US (7) US20200276276A1 (fr)
EP (2) EP4470613A3 (fr)
JP (3) JP7059195B2 (fr)
KR (4) KR20250044469A (fr)
CN (2) CN109069659B (fr)
AU (5) AU2017227962C1 (fr)
BR (1) BR112018017091A2 (fr)
CA (1) CA3015585C (fr)
DK (1) DK3423103T3 (fr)
ES (1) ES2993932T3 (fr)
FI (2) FI3423103T3 (fr)
FR (1) FR24C1045I2 (fr)
HR (1) HRP20241591T1 (fr)
HU (2) HUE069445T2 (fr)
IL (3) IL317744A (fr)
LT (2) LT3423103T (fr)
MA (2) MA45277A (fr)
MX (2) MX2018009938A (fr)
MY (2) MY208384A (fr)
NL (1) NL301298I2 (fr)
NO (1) NO2025005I1 (fr)
NZ (1) NZ745318A (fr)
PL (1) PL3423103T3 (fr)
RS (1) RS66250B1 (fr)
RU (1) RU2747316C2 (fr)
SG (1) SG11201806092TA (fr)
SI (1) SI3423103T1 (fr)
SM (1) SMT202400423T1 (fr)
WO (1) WO2017148883A1 (fr)
ZA (1) ZA201805705B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
KR20250044469A (ko) * 2016-03-01 2025-03-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
NZ751969A (en) 2016-09-29 2023-04-28 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CN109789221B (zh) * 2016-09-29 2022-11-01 阿森迪斯药物骨疾病股份有限公司 控释pth的药物组合物
LT3518961T (lt) 2016-09-29 2023-05-10 Ascendis Pharma Bone Diseases A/S Pth junginiai, pasižymintys mažu didžiausios ir mažiausios koncentracijos santykiu
WO2019178462A1 (fr) * 2018-03-16 2019-09-19 The General Hospital Corporation Conjugués polypeptes-hormone parathyroïde et leurs procédés d'utilisation
SG11202007524QA (en) * 2018-03-28 2020-09-29 Ascendis Pharma Oncology Div A/S Il-2 conjugates
EP3793587B1 (fr) * 2018-05-18 2025-07-02 Ascendis Pharma Bone Diseases A/S Dose de départ de conjugués de pth
AU2020216361A1 (en) * 2019-01-29 2021-08-12 Takeda Pharmaceutical Company Limited Parathyroid hormone variants
KR20250171437A (ko) 2019-02-11 2025-12-08 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
MX2022007371A (es) * 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.
EP4161956A1 (fr) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Séquences d'il-2 et leurs utilisations
TWI888383B (zh) * 2020-06-19 2025-07-01 丹麥商阿森迪斯藥物骨疾病股份有限公司 Ｐｔｈ綴合物的液體藥物製劑
WO2021263040A1 (fr) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Formulations de pepticorps stables
AU2021319863A1 (en) 2020-08-05 2023-02-16 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
AU2023353057A1 (en) 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone
EP4611891A1 (fr) 2022-11-02 2025-09-10 Ascendis Pharma Bone Diseases A/S Régime de traitement à base de pth comprenant deux composés pth
WO2025051711A1 (fr) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Traitement par pth d'une maladie rénale chronique
CN118638210B (zh) * 2024-08-14 2024-11-15 南方医科大学第三附属医院（广东省骨科研究院） 长效pth类似物的制备方法及应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1477496A4 (fr) 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd Pth a liaison peg ou derive de pth a liaison peg
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PT1620118E (pt) 2003-04-08 2014-10-16 Yeda Res & Dev Fármacos peguilados de modo reversível
JP4133570B2 (ja) * 2003-05-15 2008-08-13 アルパイン株式会社 ナビゲーション装置
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
TW200526254A (en) * 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
CN1657540A (zh) * 2004-02-18 2005-08-24 中国人民解放军军事医学科学院基础医学研究所 人甲状旁腺素（1－34）的聚乙二醇化衍生物，含有它们的药物组合物及用途
JP4950022B2 (ja) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
WO2005115441A2 (fr) 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions et methodes ameliorees d'administration par les muqueuses de l'hormone parathyroide
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) * 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20060045912A1 (en) 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
NO325064B1 (no) * 2006-07-06 2008-01-28 Tandberg Telecom As Kommunikasjonsklient
CN101534643A (zh) 2006-09-15 2009-09-16 安佐制药股份有限公司 用于递送寡核苷酸的基于位阻酯的生物可降解连接体
MX2009003740A (es) 2006-10-13 2009-04-22 Lilly Co Eli Pth pegilado como moduladores de receptor pth y usos de los mismos.
US8101729B2 (en) 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
JP5520811B2 (ja) 2007-04-09 2014-06-11 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
PL2369005T3 (pl) 2007-06-21 2013-10-31 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i(lub) in vitro
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
EP2052736A1 (fr) 2007-10-26 2009-04-29 Nycomed Danmark ApS Formulations d'hormones parathyroïdiennes et leurs utilisations
ES2733355T3 (es) 2008-02-01 2019-11-28 Ascendis Pharma As Profármaco que comprende un enlazador autoescindible
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (fr) 2008-06-25 2009-12-30 Ascendis Pharma As Bnp pégylé
US20110195900A1 (en) 2008-08-19 2011-08-11 Ferring B.V. Peptidic pth receptor agonists
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP2459227B1 (fr) 2009-07-31 2021-03-17 Ascendis Pharma A/S Promédicaments contenant une amine aromatique liée à un support par liaison amide
WO2011012723A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Compositions injectables à libération prolongée contenant un promédicament du pramipexole
WO2011012721A1 (fr) 2009-07-31 2011-02-03 Ascendis Pharma As Promédicaments de pramipexole liés à un support
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
JP5732053B2 (ja) 2009-07-31 2015-06-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 持続型インスリン組成物
EP2459220B1 (fr) 2009-07-31 2020-09-09 Ascendis Pharma A/S Hydrogels biodégradables insolubles dans l'eau à base de polyéthylène glycol
EP2485767A1 (fr) 2009-10-06 2012-08-15 Ascendis Pharma A/S Promédicaments à base de palipéridone liée à un support
CA2783296C (fr) * 2009-12-15 2019-01-15 Ascendis Pharma As Composition d'hormone de croissance
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011089216A1 (fr) 2010-01-22 2011-07-28 Ascendis Pharma As Lieurs de précurseurs à base de dipeptides pour des médicaments contenant des amines aliphatiques
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US20110229580A1 (en) 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
EP3372617B1 (fr) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
EP2566335B1 (fr) 2010-05-05 2016-06-29 Prolynx Llc Libération contrôlée de principes actifs à partir de conjugués macromoléculaires
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
MX357674B (es) 2010-05-21 2018-07-18 Xl Protein Gmbh Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
WO2012002047A1 (fr) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 Procédé de détermination d'attributs, dispositif de détermination d'attributs, programme, support d'enregistrement et système de détermination d'attributs
US20120040320A1 (en) 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (fr) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Promédicaments comprenant un conjugué de liaison d'exendine
US20140243254A1 (en) 2011-08-12 2014-08-28 Ascendis Pharma A/S Polymeric Hyperbranched Carrier-Linked Prodrugs
US9872864B2 (en) 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
CA2843506C (fr) 2011-08-12 2020-05-12 Ascendis Pharma A/S Promedicaments relies a des supports comprenant des liaisons ester carboxylique reversibles
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
IN2014CN00989A (fr) 2011-08-12 2015-04-10 Ascendis Pharma As
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
BR112014008789A2 (pt) 2011-10-12 2017-04-25 Ascendis Pharma Ophthalmology Div As prevenção e tratamento de condições oculares
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
WO2013108235A1 (fr) 2012-01-20 2013-07-25 Lupin Limited Formulation de pth stabilisée
AU2013254756B2 (en) 2012-04-25 2017-03-30 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US9718868B2 (en) * 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
CN104755104A (zh) * 2012-10-11 2015-07-01 阿森迪斯药物股份有限公司 诊断、预防和治疗关节疾病
MY177912A (en) 2012-10-11 2020-09-25 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
CN104781314B (zh) 2012-10-11 2017-11-14 阿森迪斯药物股份有限公司 水凝胶前药
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
JP6290243B2 (ja) 2012-12-07 2018-03-07 アセンディス ファーマ エー／エス 担体連結プロスタノイドプロドラッグ
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
AU2014257745B2 (en) 2013-04-22 2018-10-04 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
AU2014333954C1 (en) 2013-10-08 2020-08-27 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (fr) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptides inhibiteurs de l'interaction TEAD/YAP-TAZ
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
KR102599552B1 (ko) 2015-01-09 2023-11-06 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 프로드럭
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
KR20250044469A (ko) 2016-03-01 2025-03-31 아센디스 파마 본 디지즈 에이/에스 Pth 프로드럭
NZ751969A (en) 2016-09-29 2023-04-28 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
LT3518961T (lt) * 2016-09-29 2023-05-10 Ascendis Pharma Bone Diseases A/S Pth junginiai, pasižymintys mažu didžiausios ir mažiausios koncentracijos santykiu
CN109789221B (zh) * 2016-09-29 2022-11-01 阿森迪斯药物骨疾病股份有限公司 控释pth的药物组合物
RU2768747C2 (ru) * 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
EP3793587B1 (fr) * 2018-05-18 2025-07-02 Ascendis Pharma Bone Diseases A/S Dose de départ de conjugués de pth
KR20250171437A (ko) * 2019-02-11 2025-12-08 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
MX2022007371A (es) 2020-01-13 2022-07-12 Ascendis Pharma Bone Diseases As Tratamiento del hipoparatiroidismo.

Also Published As

Publication number Publication date
HUS2500009I1 (hu) 2025-02-28
NZ785623A (en) 2024-10-25
AU2022256158B2 (en) 2023-09-28
FIC20250008I1 (fi) 2025-02-03
BR112018017091A2 (pt) 2019-01-02
JP2025000652A (ja) 2025-01-07
RS66250B1 (sr) 2024-12-31
ZA201805705B (en) 2019-06-26
NL301298I2 (nl) 2024-12-11
JP7059195B2 (ja) 2022-04-25
CN109069659B (zh) 2022-04-19
KR102331820B1 (ko) 2021-11-29
AU2020286303B2 (en) 2022-07-21
CN115025239B (zh) 2025-03-21
HRP20241591T1 (hr) 2025-02-28
AU2017227962C1 (en) 2021-05-13
AU2023285850B2 (en) 2025-09-18
US20230121525A1 (en) 2023-04-20
KR102786270B1 (ko) 2025-03-24
SMT202400423T1 (it) 2024-11-15
PL3423103T3 (pl) 2025-02-10
KR20230015517A (ko) 2023-01-31
AU2017227962B2 (en) 2020-11-12
NO2025005I1 (no) 2025-01-14
IL260756B1 (en) 2023-05-01
CA3015585C (fr) 2025-09-23
MA45277A (fr) 2019-01-09
HUE069445T2 (hu) 2025-03-28
US12214020B2 (en) 2025-02-04
AU2020286303C1 (en) 2023-03-02
FI3423103T3 (fi) 2024-11-20
NZ745318A (en) 2023-01-27
US20240123038A1 (en) 2024-04-18
EP3423103B1 (fr) 2024-09-11
KR20180118197A (ko) 2018-10-30
AU2023285850A1 (en) 2024-01-18
FR24C1045I1 (fr) 2025-01-10
MX2018009938A (es) 2019-03-14
CN115025239A (zh) 2022-09-09
LTPA2025506I1 (fr) 2025-02-25
DK3423103T3 (da) 2024-09-30
RU2747316C2 (ru) 2021-05-04
RU2018134135A (ru) 2020-04-01
IL260756A (fr) 2018-09-20
CA3015585A1 (fr) 2017-09-08
WO2017148883A1 (fr) 2017-09-08
LT3423103T (lt) 2024-10-25
EP3423103A1 (fr) 2019-01-09
FR24C1045I2 (fr) 2025-10-10
JP2019513127A (ja) 2019-05-23
AU2017227962A1 (en) 2018-08-09
KR102524255B1 (ko) 2023-04-20
AU2022256158A9 (en) 2023-09-28
KR20250044469A (ko) 2025-03-31
IL260756B2 (en) 2023-09-01
JP2022068210A (ja) 2022-05-09
IL301616B1 (en) 2025-01-01
EP4470613A2 (fr) 2024-12-04
ES2993932T3 (en) 2025-01-14
IL317744A (en) 2025-02-01
US20220008516A1 (en) 2022-01-13
AU2020286303A1 (en) 2021-02-04
SI3423103T1 (sl) 2024-12-31
MY196308A (en) 2023-03-24
EP4470613A3 (fr) 2025-03-12
US11793861B2 (en) 2023-10-24
RU2018134135A3 (fr) 2020-04-01
SG11201806092TA (en) 2018-08-30
IL301616A (en) 2023-05-01
US20200360487A1 (en) 2020-11-19
MA45809B1 (fr) 2024-12-31
US20200376089A1 (en) 2020-12-03
JP7619973B2 (ja) 2025-01-22
AU2025279737A1 (en) 2026-01-15
MX2022015755A (es) 2023-01-19
US20250268988A1 (en) 2025-08-28
AU2022256158A1 (en) 2022-12-08
US20200276276A1 (en) 2020-09-03
CN109069659A (zh) 2018-12-21
KR20210147085A (ko) 2021-12-06
IL301616B2 (en) 2025-05-01
MY208384A (en) 2025-05-05

Similar Documents

Publication Publication Date Title
MA45809A (fr) Promédicaments de pth
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
CY1123920T1 (el) Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου
MX379270B (es) Composiciones que comprenden cepas bacterianas.
MA41887A1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
EP3313530A4 (fr) Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci
MX2018003696A (es) Composicion acida que comprende una ficocianina.
EP3399978A4 (fr) Composés antiprolifératifs, leurs compositions pharmaceutiques et leurs utilisations
EP3340988A4 (fr) Composés inhibiteurs de canaux ioniques, formulations pharmaceutiques, et utilisations
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA202090402A1 (ru) Фармацевтическая композиция, содержащая пальбоциклиб
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
JO3456B1 (ar) فيروتيوكسيتين بيروجلوتامات
MX383940B (es) Formulación farmacéutica que contiene tocol fosfato.
AU2016361427A8 (en) Platinum anticancer agents
EP3856242A4 (fr) Anticorps anti-siglec, composition pharmaceutique le comprenant, et leurs utilisations
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir
JP2019094024A5 (fr)
JP2019058493A5 (fr)
NO20161136A1 (en) Compounds and compositions for biofilm prevention
MA51826A (fr) Compositions pharmaceutiques comprenant de la teixobactine